IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells

Stem Cells

Volumn 31, Issue 4, 2013, Pages 627-640

  Osuka, Satoru ^a,b   Sampetrean, Oltea ^b,c   Shimizu, Takatsune ^b,d   Saga, Isako ^b   Onishi, Nobuyuki ^b   Sugihara, Eiji ^b,c   Okubo, Jun ^b,e   Fujita, Satoshi ^b,f   Takano, Shingo ^a   Matsumura, Akira ^a   Saya, Hideyuki ^b,c  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d HOSHI UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Cancer stem cell; Forkhead box O; Glioblastoma; Insulin like growth factor 1; Radioresistance

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER STEM CELL; DOWN REGULATION; GLIOMA; HUMAN; HUMAN CELL; RADIATION DOSE FRACTIONATION; RADIATION PROTECTION; RADIOSENSITIVITY; UPREGULATION;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORKHEAD TRANSCRIPTION FACTORS; GLIOMA; HUMANS; IMMUNOBLOTTING; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, INBRED C57BL; NEOPLASTIC STEM CELLS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

MURINAE;

EID: 84875767442     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1328     Document Type: Article

References (61)

1. Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci (Elite Ed) 2012;4:2142-2149.
2. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
3. Chen J, Li Y, Yu TS et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012;488: 522-526.
4. Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature 2004;432:396-401.
5. Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
6. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/ CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006;98:1777-1785.
7. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
8. Kim MJ, Kim RK, Yoon CH et al. Importance of PKCdelta signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment. J Cell Sci 2011;124:3084-3094.
9. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J Natl Cancer Inst 2006;98: 1755-1757.
10. Woodward WA, Chen MS, Behbod F et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA 2007;104:618-623.
11. Tamura K, Aoyagi M, Wakimoto H et al. Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation. J Neurosurg 2010;113: 310-318.
12. Bensimon J, Altmeyer-Morel S, Benjelloun H et al. CD24(-/low) stem-like breast cancer marker defines the radiation-resistant cells involved in memorization and transmission of radiation-induced genomic instability. Oncogene 2013;32:251-258.
13. Vlashi E, Kim K, Lagadec C et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009;101:350-359.
14. Wang J, Wakeman TP, Lathia JD et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010;28:17-28.
15. Reguart N, He B, Taron M et al. The role of Wnt signaling in cancer and stem cells. Future Oncol 2005;1:787-797.
16. Hsieh A, Ellsworth R, Hsieh D. Hedgehog/GLI1 regulates IGF dependent malignant behaviors in glioma stem cells. J Cell Physiol 2011;226:1118-1127.
17. Hatanpaa KJ, Burma S, Zhao D et al. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 2010;12:675-684.
18. Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141: 69-80.
19. Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulinlike growth factor-I receptor inhibition. Cancer Res 2009;69: 1951-1957.
20. Eckstein N, Servan K, Hildebrandt B et al. Hyperactivation of the insulin- like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 2009;69:2996-3003.
21. Buck E, Eyzaguirre A, Rosenfeld-Franklin M et al. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008; 68:8322-8332.
22. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-3083.
23. Macaulay VM, Salisbury AJ, Bohula EA et al. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 2001;20:4029-4040.
24. Bartucci M, Morelli C, Mauro L et al. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001;61:6747-6754.
25. Robbins DJ, Cheng M, Zhen E et al. Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc Natl Acad Sci USA 1992;89:6924-6928.
26. Valenciano A, Henriquez-Hernandez LA, Moreno M et al. Role of IGF-1 receptor in radiation response. Transl Oncol 2012;5:1-9.
27. Medyouf H, Gusscott S, Wang H et al. High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 2011; 208:1809-1822.
28. Qiu W, Leibowitz B, Zhang L et al. Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis. Oncogene 2010;29: 1622-1632.
29. Sampetrean O, Saga I, Nakanishi M et al. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 2011;13:784-791.
30. Shimizu T, Ishikawa T, Sugihara E et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29:5687-5699.
31. Fujino RS, Tanaka K, Morimatsu M et al. Spermatogonial cell-mediated activation of an IkappaBzeta-independent nuclear factor-kappaB pathway in Sertoli cells induces transcription of the lipocalin-2 gene. Mol Endocrinol 2006;20:904-915.
32. Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004;23: 9392-9400.
33. Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66:7843-7848.
34. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin- 4. Cell Stem Cell 2007;1:389-402.
35. Todaro M, Perez Alea M, Scopelliti A et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008;7: 309-313.
36. Tang KH, Ma S, Lee TK et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012;55:807-820.
37. Trojan J, Blossey BK, Johnson TR et al. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Proc Natl Acad Sci USA 1992;89: 4874-4878.
38. Trojan J, Johnson TR, Rudin SD et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin- like growth factor I RNA. Science 1993;259:94-97.
39. Trojan J, Duc HT, Upegui-Gonzalez LC et al. Presence of MHC-I and B-7 molecules in rat and human glioma cells expressing antisense IGF-I mRNA. Neurosci Lett 1996;212:9-12.
40. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
41. Daitoku H, Sakamaki J, Fukamizu A. Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011;1813:1954-1960.
42. Brownawell AM, Kops GJ, Macara IG et al. Inhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX. Mol Cell Biol 2001;21:3534-3546.
43. van den Berg MC, Burgering BM. Integrating opposing signals toward Forkhead box O. Antioxid Redox Signal 2011;14:607-621.
44. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: A target for the management of cancer. Toxicol Appl Pharmacol 2007;224:360-368.
45. Renault VM, Rafalski VA, Morgan AA et al. FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 2009;5:527-539.
46. Diehn M, Cho RW, Lobo NA et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458:780-783.
47. Beier D, Hau P, Proescholdt M et al. CD133(+) and CD133(-) glioblastoma- derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007;67:4010-4015.
48. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-296.
49. Muerkoster S, Wegehenkel K, Arlt A et al. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin- 1beta. Cancer Res 2004;64:1331-1337.
50. Ivanov VN, Zhou H, Ghandhi SA et al. Radiation-induced bystander signaling pathways in human fibroblasts: A role for interleukin-33 in the signal transmission. Cell Signal 2010;22: 1076-1087.
51. Hellawell GO, Turner GD, Davies DR et al. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62:2942-2950.
52. All-Ericsson C, Girnita L, Seregard S et al. Insulin-like growth factor-1 receptor in uveal melanoma: A predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci 2002;43:1-8.
53. Nickerson T, Chang F, Lorimer D et al. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61:6276-6280.
54. Yu D, Watanabe H, Shibuya H et al. Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 2003;278:6702-6709.
55. Iwasa T, Okamoto I, Suzuki M et al. Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009;15:5117-5125.
56. Wang YH, Wang ZX, Qiu Y et al. Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009;327:257-266.
57. Allen GW, Saba C, Armstrong EA et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007;67:1155-1162.
58. Yavari K, Taghikhani M, Maragheh MG et al. SiRNA-mediated IGF- 1R inhibition sensitizes human colon cancer SW480 cells to radiation. Acta Oncol 2010;49:70-75.
59. Cosaceanu D, Carapancea M, Castro J et al. Modulation of response to radiation of human lung cancer cells following insulin- like growth factor 1 receptor inactivation. Cancer Lett 2005;222:173-181.
60. Friedlander TW, Weinberg VK, Huang Y et al. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep 2012;27:3-9.
61. Quek R, Wang Q, Morgan JA et al. Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res 2011;17:871-879.